Vlp Therapeutics Raises $21M Series A-1 For Cancer Treatment Vaccine, Infectious Diseases Vaccine R&D

Dec 27, 2021•over 3 years ago

Amount Raised

$21 Million

Round Type

series a

Gaithersburg

Description

US-based biotech company VLP Therapeutics, Inc. (VLPT) announced on December 27 that it has signed an agreement for an investment of US$21 million in a Series A-1 round from six investors, consisting of two new investors: Nobelpharma Co., Ltd. and MUFG Bank, Ltd., and four existing investors: Sojitz Corporation, MIYAKO Capital Co., Ltd., Mr. Robert G

Company Information

Company

Vlp Therapeutics

Location

Gaithersburg, Maryland, United States

About

VLP Therapeutics, Inc. (VLPT), co-founded in 2013 by Drs. Wataru Akahata, Ryuji Ueno, and Sachiko Kuno, is a Gaithersburg, MD-based biotech company with a mission to address unmet medical needs worldwide and expand the frontiers of vaccine treatment. Led by CEO Akahata VLPT is currently engaged in research and development of a cancer treatment vaccine as well as prophylactic vaccines against malaria, dengue, etc. using VLPT's proprietary platform technologies. [https://vlptherapeutics.com/]

Funding Insights

Based on industry data

Tech investment trends

83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech